Xerostomia (Dry Mouth) Therapeutics

Xerostomia (Dry Mouth) Therapeutics

Global Xerostomia (Dry Mouth) Therapeutics Market to Reach US$1.0 Billion by 2030

The global market for Xerostomia (Dry Mouth) Therapeutics estimated at US$770.4 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. Over-the-Counter Xerostomia Drugs, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$603.6 Million by the end of the analysis period. Growth in the Prescription Xerostomia Drugs segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$204.7 Million While China is Forecast to Grow at 6.0% CAGR

The Xerostomia (Dry Mouth) Therapeutics market in the U.S. is estimated at US$204.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$209.5 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Xerostomia (Dry Mouth) Therapeutics Market - Key Trends and Drivers Summarized

Xerostomia, commonly known as dry mouth, is a condition characterized by a decrease in saliva production, which can lead to various complications such as difficulty in swallowing, dental decay, and oral infections. This condition can arise from multiple sources including side effects from certain medications, underlying medical issues, exposure to radiation therapy, and natural aging processes. Xerostomia therapeutics encompass a range of treatments designed to alleviate these symptoms and restore moisture to the mouth. These treatments include saliva substitutes, oral moisturizers, medications that stimulate saliva production, and lifestyle changes aimed at enhancing oral hydration.

The demand for xerostomia therapeutics is primarily driven by the rising prevalence of chronic diseases such as diabetes, Sjögren`s syndrome, and Parkinson’s disease, which are commonly associated with dry mouth. An aging global population, which is more susceptible to these chronic conditions, further compounds the demand for effective treatments. Additionally, the increasing awareness and diagnosis of xerostomia, coupled with improvements in healthcare infrastructure that allow for better management of symptoms associated with the condition, also contribute to the growth of the market. The pharmaceutical development of new agents that can effectively stimulate saliva production without significant side effects is another significant driver that is likely to spur the demand for these therapeutics.

Recent trends in the xerostomia therapeutics market include the development of more advanced formulation technologies and drug delivery systems designed to improve the efficacy and convenience of treatments. For example, the use of mucoadhesive agents that can be applied directly to the mucosa for prolonged action and enhanced symptom relief is gaining traction. There is also a noticeable shift towards natural and herbal remedies, reflecting a broader consumer preference for organic and less invasive treatment options. On the regulatory front, there is increased support for the research and development of innovative therapeutics, facilitated by grants and approvals from bodies such as the FDA, which streamline the pathway for bringing new treatments to market. In recent developments, innovative treatments like glandular regeneration and gene therapy have shown promise, particularly for patients who have developed xerostomia as a consequence of radiation therapy. These cutting-edge approaches aim to restore normal function to the salivary glands, offering hope for a more permanent solution to the challenges posed by xerostomia. As research continues to advance, these therapies highlight the progressive shift towards more targeted and regenerative treatment strategies in the management of dry mouth, aligning with broader trends in medical science that emphasize restoration and healing at a cellular level.

Select Competitors (Total 36 Featured) -

• 3M company
• Advanz Pharma Corp. Limited
• Bausch Health Companies Inc.
• Fresenius SE & Co. KGaA
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Parnell Pharmaceuticals Inc.
• Pharmascience Inc (Pendopharm)
• Quest Products Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.